On Tuesday, the U.S. Supreme Court will hear a case that questions the dangers of mifepristone: the abortion drug. The Food and Drug Administration is accused of overlooking serious safety problems as they have loosened regulations over the years.
With pro-life states making abortion more difficult to access, the drug has become increasingly popular. There were over a million abortions last year alone – and mifepristone is given much of the credit. Over 60 percent of abortions last year were done through medication.
The Fifth Circuit Court of Appeals ruled the FDA failed to follow proper procedures when loosening regulations. The Biden administration and the manufacturer of the drug are hoping the Supreme Court will reverse that ruling.
Joining us now is Rev. Jim Harden, CEO for CompassCare, which runs several pregnancy centers across the United States.
Q&A
1. What does mifepristone do?
2. Most understand it kills babies. But what does it do to women?
3. The FDA made a series of changes over the years regarding Mifepristone, including allowing it to be used later in pregnancy. Why are they doing this?
4. How do you believe the Supreme Court will handle this case?
5. Could this case have an impact on the 2024 election? How so?
6. Do you believe most Americans are okay with this drug and what it does? Do they even understand it?
7. Why do you suppose the left is so obsessed with abortion?
8. Where can people go to learn more about CompassCare and what your team is doing?
About James Harden
Rev. James Harden, a dedicated pro-life advocate and leader of CompassCare, is known for his outspoken views on medical ethics, executive leadership, and pro-life strategy. With a family of ten children and a strong moral compass, he believes in the adage, “Money follows morality.” Harden has been vocal about perceived corruption in federal law enforcement and public policy in post-Roe America. His predictions about the Dobbs decision in 2018 and the demise of the “Red Wave” in 2022 showcase his deep understanding of the political landscape.
CONTACT:
For further details or to arrange the interview, please contact Jerry McGlothlin at geraldmcg@outlook.com or 919-437-0001.
